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INTRODUCTION 
 Regional anaesthesia is a safe, inexpensive technique with the 
advantage of prolonged postoperative pain relief. Effective treatment of 
postoperative pain blunts autonomic, somatic, and endocrine responses. It 
has become a common practice to use a polypharmacological approach 
for the treatment of  postoperative pain, because no drug has yet been 
identified that specifically inhibits nociception without associated side 
effects.1 
 Magnesium is the fourth most plentiful cation in the body. It has 
anti-nociceptive effects in animal and human models of pain.2,3  These 
effects are primarily based on the regulation of calcium influx into the 
cell, that is natural physiological calcium antagonism and antagonism of   
N-methyl-D-aspartate receptor.1  It has been reported that intrathecal 
magnesium enhances opioid anti-nociception in an acute incisional 
model.3  These effects have prompted the investigation of magnesium as 
an adjuvant for postoperative analgesia. There are studies concerning 
different routes of magnesium administration such as i.v or intrathecally 
or epidurally that improve anaesthetic and analgesic quality.1 4-6 
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This study is designed  to assess the effectiveness of using 
intrathecal and epidural magnesium (Mg )  in reducing intra and post 
operative analgesic requirements and to compare the quality of analgesia 
of intrathecal bupivacaine-fentanyl-magnesium mixture with intrathecal 
bupivacaine-fentanyl mixture.            
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AIMS AND OBJECTIVES 
1. To assess the effectiveness of using intrathecal and epidural 
magnesium   (Mg )  in reducing intra and post operative analgesic 
requirements. 
 
2. To compare the quality of analgesia of intrathecal bupivacaine-
fentanyl-magnesium mixture with intrathecal bupivacaine-fentanyl 
mixture. 
 
3. To evaluate the hemodynamic response of intrathecal and epidural 
magnesium. 
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PHYSIOLOGY OF PAIN 
DEFINITION OF PAIN 
           The International Association for the Study of Pain (IASP)  
defines pain as “an unpleasant sensory and emotional experience  
associated with actual or potential tissue damage or described in terms of 
such damage.” 
PHYSIOLOGY OF PAIN 
        Nociception is conveyed from the periphery to the brain at three 
levels: the peripheral nociceptor, the spinal cord, and the supra-spinal 
(brain) levels7. 
There are two types of pain- Physiological and Pathological. 
I . PHYSIOLOGICAL PAIN :is produced by stimulation of high 
threshold thermo/mechanical nociceptors, which transmit via fast 
conducting myelinated    A- delta fibres. These enter the dorsal horn of 
the spinal cord and synapse at laminae I and V.  
 
II . PATHOLOGICAL PAIN: originates from stimulation of the 
high threshold polymodal nociceptors (free endings) present in all tissues. 
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The nociceptors respond to mechanical, chemical and thermal stimuli and 
are transmitted via slow conducting unmyelinated C fibres. These 
synapse at laminae II and III (substantia gelatinosa) of the dorsal horn. 
The second order neurons are either nociceptive specific (substantia 
gelatinosa) or wide dynamic range (WDR) neurons (in laminae V and VI) 
that respond to a wide range of noxious and non-noxious input. Both 
pathways ascend up the spinal cord via the spinothalamic tracts to the 
thalamus, which synapse and project on to the somatosensory cortex. 
Inhibitory inter-neurons in the substantia gelatinosa prevent activation of 
the dorsal root ganglia. Interneurons can be activated by A- beta and 
inhibited by A- beta and C fibre activity. Pain can be gated-out by 
stimulating the large A beta fibres in the painful area. This is the working 
mechanism behind transcutaneous electrical nerve stimulation. The 
descending inhibition pathways originate at the level of the cortex and 
thalamus, and descend via the brainstem (periaqueductal grey) and the 
dorsal columns to terminate at the dorsal horn of the spinal cord. 
Neurotransmitters noradrenaline, serotonin (5-HT) and the endogenous 
opioids are released to provide antinociception. 
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EFFECTS OF POSTOPERATIVE PAIN 
POST OPERATIVE PAIN 
Effects of postoperative pain: 
Postoperative pain can affect all organ systems and includes 
Cardiovascular - increased myocardial oxygen consumption and 
ischemia. 
Respiratory  - reduced cough, atelectasis, sputum retention and 
hypoxemia 
Gastrointestinal - delayed gastric emptying, reduced gut motility 
and constipation. 
Genitourinary - urinary retention. 
Neuroendocrine - hyperglycemia, protein catabolism and sodium 
retention. 
Musculoskeletal - reduced mobility, pressure sores and increased 
risk of deep vein  thrombosis. 
Psychological - anxiety and fatigue. 
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ROLE OF EPIDURAL ANALGESIA 
Benefits of epidural analgesia 
           Use of postoperative epidural anaesthesia and analgesia especially 
with a local anaesthetic – based  analgesic solution can attenuate the 
pathophysiologic response to surgery and may be associated with a 
reduction in mortality and morbidity compared with analgesia with 
systemic opioids. 
  Rodgers et al8  demonstrated through a meta-analysis of 
randomized data that perioperative use of neuraxial anaesthesia and 
analgesia versus general anaesthesia and systemic opioids reduced 
overall mortality by approximately 30%. Use of epidural analgesia can 
decrease the incidence of postoperative gastrointestinal, pulmonary and 
cardiac complications. 
  Christopherson et al9 demonstrated that use of intra operative 
regional anaesthesia  reduced  hypercoagulable – related events (eg. 
Deep vein thrombosis, pulmonary embolism, vascular graft failure). 
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POSTOPERATIVE ANALGESIA IN 
ORTHOPAEDICS 
Postoperative pain is of major concern after orthopaedic lower limb 
surgery. Moderate to severe at rest, it is exacerbated on movement and 
particularly after hip and knee surgery and by severe reflex muscular 
spasm. This not only causes patient discomfort but also compromise the 
early physical therapy, the most influential factor on rapid postoperative 
rehabilitation and ambulation.  
Postoperative pain relief can be achieved by a number of 
techniques such as intravenous patient controlled analgesia (PCA)  or 
epidural analgesia. Effective analgesia with epidural or peripheral block 
reduces narcotic requirements, provides better analgesia, reduces 
catabolism and results in improved rates of rehabilitation after 
orthopaedic lower limb surgeries. 
The benefits of effective postoperative analgesia in orthopeadic 
surgeries was made evident by the fact that it facilitates early ambulation 
which is beneficial in the prophylaxis of deep vein thrombosis, which is a 
common problem encountered in orthopaedics10.  Postoperative 
modalities like pneumatic compression boots, foot pumps, foot exercises, 
aspirin and low dose warfarin(started the day after surgery) can be safely 
used in conjunction with epidural anaesthesia to reduce the incidence of 
deep vein thrombosis. 
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BUPIVACAINE 
Bupivacaine was introduced by Boaf Ekenstam in 1963. 
Chemical structure: bupivacaine hydrochloride is 2-
piperidenecarboxamide 1-butyl-N-(2,6 dimethylphenyl) monochloride, a 
monohydrate is a white crystalline powder that is freely  soluble in 95% 
ethanol, soluble in water and slightly soluble in chloroform or acetone. 
            It has the following structural formula: 
 
Bupivacaine is related chemically and pharmacologically to the 
amide group of local anaesthetics. It is structural homologue of 
mepivacaine. 
Presentation: bupivacaine hydrochloride is available in sterile 
isotonic solution with or without epinephrine 1:2,00,000 for injection. It 
is available in  0.25%,0.5%,0.75% concentration containing 2.5mg/dl, 
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5mg/dl, 7.5mg/dl of bupivacaine hydrochloride respectively and  sodium 
chloride, sodium hydroxide ± hydrochloric acid for pH adjustment. 
Methylparaben 1mg/ml added as preservative. 0.5%(hyperbaric ) solution 
contain 80mg/ml of glucose(with a specific gravity of  1.026)-for 
intrathecal use. 
Mechanism of action: 
 Local anaesthetics diffuse in their nonionized form through neural 
sheaths and the axonal membrane to the internal surface of the cell 
membrane sodium ion channels where they combine with hydrogen ions 
to form a cationic species which enters the internal opening of the sodium 
ion channel and combines with a receptor. This produces blockade of the 
sodium ion channels thereby decreasing sodium conductance and 
preventing depolarization of  the cell membrane. 
Pharmacological action:  
a) Central nervous system (CNS) : the principle effect of 
bupivacaine is reversible neural blockade, this leads to a characteristically 
biphasic effect on the CNS. 
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- Initially excitation: light headness, dizziness, visual and 
auditory disturbances and seizures occurs due to blockade of 
inhibitory pathways in cortex. 
- With increasing doses: CNS depression occurs due to 
depression of both facilitatory and inhibitory pathways 
leading to drowsiness, disorientation and coma. 
- Local  anaesthetic  agents  block  neuromuscular  
transmission when administered intra-arterially(formation of  
neurotransmitter, receptor and local anaesthetic complex 
which has negligible conductance). 
b) Cardiovascular system(CVS): it binds specifically to 
myocardial proteins. In toxic concentrations,the drug decreases the 
peripheral vascular resistance and myocardial contractility producing 
hypotension and possibly cardiovascular collapse. 
Routes of administration: topical, infiltration, intrathecal, 
epidural 
Dose: 2mg/kg  
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Pharmacokinetics: 
Absorption : The absorption of local anaesthetic agent is related to 
1. The site of injection (intercostals> epidural> brachial 
plexus> subcutaneous) 
2. The dose linear relationship exists between the total dose and 
the peak blood concentration achieved. 
Distribution: 95% protein bound in plasma. The volume of 
distribution is  47-103 litres. 
Metabolism: occurs in liver by N-dealkylation  primarily to 
pipcolyloxylidine. N-desbutyl bupivacaine and 4-hyroxy bupivacaine are 
also formed. 
Excretion : 5% of the dose is excreted in the urine as 
pipcolyloxylidine. 16% is excreted unchanged .The clearance is 0.47 
l/min and the elimination half life (after intravenous administration) is 
0.31-0.61 hours. 
Pharmacodynamics:  pKa of bupivacaine is 8.1, Heptane: Buffer 
partition coefficient is 27.5 
  
13
The onset and duration of conduction blockade is related to the 
pKa, lipid solubility and the extent of protein binding  of the drug. 
- A low pKa and high lipid solubility are associated with a 
rapid onset time 
-  High degree of protein binding is associated with a long 
duration of action. 
Toxicity /side effects: 
i. Allergic reactions to amide type local anaesthetics- extremely 
rare. 
ii. Intravascular injection can cause refractory cardiac depression . 
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Transdermal patches  
Lozenges 
Buccal tablets 
Mechanism of action : 
Fentanyl is a highly selective µ receptor agonist involved 
specifically in mediation of pain. It appears to act by increasing 
intracellular calcium concentration which in turn increases potassium 
conductance and hyperpolarisation of excitable cell membranes. The 
decrease in membrane excitability decreases both pre- and post synaptic 
responses. 
Pharmacological actions : 
Cardiovascular system : The most significant cardiovascular 
effect is bradycardia. Fentanyl obtunds the cardiovascular responses to 
laryngoscopy and intubation. Cardiac output, mean arterial pressure, 
pulmonary and systemic vascular resistance and pulmonary capillary 
wedge pressure are unaffected. 
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Respiratory system : Fentanyl is a potent respiratory depressant 
causing a decrease in both respiratory rate and tidal volume. It also 
diminishes respiratory drive to hypoxia and hypercapnia. Chest wall 
rigidity may occur.  
Central nervous system : Fentanyl is 50-80 times more potent 
than morphine as an analgesic. It has little hypnotic and sedative activity. 
Miosis is produced by stimulation of Edinger-Westphal nucleus.  
Gastrointestinal system : Fentanyl decreases gastrointestinal 
motility and decreases gastric acid secretion. It increases common  bile 
duct pressure by causing spasm of sphincter of Oddi. 
Pharmacokinetics : 
Absorption : Fentanyl is absorbed when administered orally. Oral 
bioavailability is 33%. Transdermal route has 92% bioavailability. 
Fentanyl when given through buccal route has 50% bioavailability. 
Distribution : Fentanyl is 80 -85% protein bound in plasma with 
volume of distribution of 0.88-4.41 l/kg. Fentanyl is more lipid soluble 
than morphine and thus crosses blood brain barrier easily. It thus has 
more rapid onset of action than morphine. 
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Metabolism : Fentanyl is primarily metabolized in liver by 
Cytochrome     P-450 3A4  by  N-dealkylation  and  hydrolysis. 
Excretion : The metabolites of fentanyl are excreted by kidneys. 
10% of unchanged drug is excreted by kidneys. The elimination half life 
is 1.5 to 6 hrs. 
Side effects / toxicity : Nausea and vomiting are the most common 
side effects.  Wooden chest syndrome may occur in some patients. At 
higher doses respiratory depression may occur. 
Uses : 
1. To provide analgesia component of general anaesthesia. 
2. Used along with benzodiazepine to produce procedural sedation 
for endoscopy, cardiac catheterization. 
3. As an adjuvant in spinal and epidural anaesthesia. 
4. In cancer therapy and chronic pain management. 
  
  
18
MAGNESIUM 
Magnesium was discovered in 1755 by Sir Humpry Davy. 
Magnesium is the fourth plentiful cation in the body and second 
most abundant intracellular cation after potassium. It is a cofactor in 
hundreds of enzymatic reactions. 
Magnesium is a natural calcium antagonist. 
Normal physiology : 
Magnesium is a bivalent cation with atomic weight of 24.312. 
Human body contains one mole ( 24 gms ) of magnesium of which 60% 
is present in bones, 20% is in muscles, 20% is in soft tissues. Only 1% of 
total body magnesium is present extracellularly. 
         Intracellular magnesium exists largely ( 90% ) in bound form in 
ATP molecules of cytoskeleton ( nucleus, mitochondria & reticulum ). 
Only a small portion ( 5 – 14% ) remains as ionized form within the cell. 
Properties of Magnesium : 
1. Magnesium intervenes in the activation of Ca ATPase & Na-
K ATPase involved in transmembrane ion exchange. It acts as a stabilizer 
of cell membrane and intracytoplasmic charges. 
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2. Magnesium has antagonist action on L type calcium 
channels. It inhibits Ca inflows into the cell and outflow of Ca from 
sarcoplasmic reticulum. 
3. Magnesium has antagonist effect on N-methyl D-aspartate 
receptors in nervous system. 
4. Intracellular ionized magnesium is involved in 
phosphorylation & is necessary for activation of hundreds of enzymatic 
reactions concerning ATP. 
Normal serum concentration :  
1.6 to 2.6 mEq /L 
Pharmacological Effects : 
Cardiovascular system : Magnesium causes vasodilatation and 
may cause hypotension at high doses. It slows the rate of SA node 
impulse formation and prolongs SA node conduction time, the PR 
interval and AV nodal effective refractory period. Magnesium attenuates 
both vasoconstrictor and arrythmogenic actions of adrenaline. 
Respiratory system : Magnesium is an effective bronchodilator 
and attenuates hypoxic pulmonary vasoconstriction. 
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Central nervous system : Magnesium is a CNS depressant and 
exhibits anticonvulsant properties. High concentrations inhibit 
catecholamine release from adrenergic nerve terminals and adrenal 
medulla. 
Gastrointestinal system : Magnesium sulphate acts as osmotic 
laxative when administered orally. 
Genito urinary system : Magnesium has renal vasodilator and 
diuretic effect. 
Toxicity / side effects : 
Minor side effects include warmth, flushing, nausea, headache and 
dizziness. Dose related side effects include somnolence, areflexia, AV 
and intraventricular conduction disorders, progressive muscle weakness, 
and cardiac arrest. 
Uses : 
1. Replacement therapy for hypomagnesemia. 
2. Magnesium sulfate is the first-line antiarrhythmic agent for 
torsades de pointes in cardiac arrest under the 2005 ECC 
guidelines and for managing quinidine-induced arrhythmias. 
3. To  treat eclampsia and premature labour in pregnant women. 
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4. As a bronchodilator after beta-agonist and anticholinergic agents 
have been tried, e.g. in severe exacerbations of asthma. 
5. In surgery for pheochromocytoma and cardiac surgery. 
6. During  anaesthetic induction to blunt intubation response. 
7. Adjuvant in intraoperative analgesia. 
8.  Oral magnesium sulphate is used as saline laxative. 
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REVIEW OF LITERATURE 
1. Role of magnesium sulfate in postoperative analgesia 
 Tramer MR et al in 1996 conducted one of the earliest studies to 
demonstrate the anti nociceptive characteristics of magnesium. METHOD 
: In a randomized double – blind study, they included 42 ASA I and II 
patients undergoing abdominal hysterectomy. Study group received 15 ml 
of 20% magnesium before start of surgery and an infusion of  2.5 ml/hr 
for next 20 hrs.  Control group received same amount of normal saline .  
Maximum expiratory flow (peak flow), pain at rest and during peak flow 
and discomfort were evaluated up to the 48th postoperative hour and 1 
week and 1 month after surgery. Insomnia was evaluated after the first 
and second postoperative nights. CONCLUSION: They concluded  that 
the perioperative application of magnesium sulphate is associated with 
smaller analgesic requirement, less discomfort, and a better quality of 
sleep in the postoperative period but not with adverse effects. ( 
Anaesthesiology;1996:84(2) 340-7).  
2. Magnesium sulphate reduces intra- and postoperative 
analgesic requirements 
 Koinig H, Wallner T, Marhofer P, Andel H, Hörauf K, Mayer N   
in 1998 performed a randomized double blind study in 46 ASA I and II 
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patients undergoing knee arthroscopy under total iv anaesthesia. 
METHOD : The patients received either magnesium sulfate 50 mg/kg 
preoperatively and 8 mg/kg/hr  intraoperatively or the same volume of 
isotonic sodium chloride solution. i.v. anaesthesia was performed with 
propofol (2 mg/kg for induction, 6-8 mg/kg/hr for maintenance), fentanyl 
(3 µg/kg for induction), and vecuronium (0.1 mg/kg for intubation). 
Intraoperative pain was defined as an increase of mean arterial blood 
pressure and heart rate of more than 20% from baseline values after the 
induction of anesthesia and was treated with bolus fentanyl (1-2 µg/kg). 
Postoperative analgesia was achieved with fentanyl (0.5 µg/kg) and 
evaluated using the pain visual analog scale for 4 hr. CONCLUSION : 
They concluded that, in a clinical setting with almost identical levels of 
surgical stimulation, i.v. magnesium sulfate administration reduces 
intraoperative and postoperative analgesic requirements.  ( Anesth Analg 
1998;87(1):206-10 ).  
3. A comparative study with oral nifedipine, intravenous 
nimodipine and magnesium sulfate in postoperative analgesia 
 Zarauza R  et  al  in  2000  tested the ability of two L-type calcium 
channel blockers (nifedipine and nimodipine) and the N-methyl D-
aspartate natural antagonist magnesium to decrease morphine 
requirements and pain in the postoperative period in 92 patients 
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undergoing elective colorectal surgery.  METHOD :  In a randomized, 
double-blinded study, patients were assigned to one of four groups. The 
control group received placebo. The nifedipine group received 60 mg of 
oral nifedipine. The magnesium group received an initial dose of 30 
mg/kg followed by 10 mg/kg/hr of magnesium sulphate over 20 h. The 
nimodipine group received 30 microg /kg/hr  of nimodipine over 20 h. 
Postoperative morphine consumption was assessed for 48 h. Pain at rest 
and pain on movement were assessed up to the fifth day postsurgery.  
CONCLUSION:  They  concluded  the perioperative application of oral 
nifedipine, IV nimodipine, or IV magnesium sulfate failed to decrease 
postoperative morphine requirements after colorectal surgery. ( Anaesth 
Analg 2000;91(4):938-43 ). 
4. Magnesium infusion reduces perioperative pain 
 Kara H, Sahin N, Ulusan V, Aydogdu T   in  2002  conducted  a  
study  to  determine whether perioperative infusion of magnesium would 
reduce postoperative pain and anxiety.  METHOD:  Twenty-four patients, 
undergoing elective hysterectomy, received a bolus of 30 mg/kg  
magnesium sulphate or the same volume of isotonic sodium chloride 
solution intravenously before the start of surgery and 0.5 g/hr  infusion 
for the next 20 hr.  Intraoperative and postoperative analgesia were 
achieved with fentanyl and morphine respectively. Patients were 
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evaluated pre- and postoperatively for anxiety. CONCLUSION: 
Continuous magnesium infusion, including the pre-, intra-, and 
postoperative periods reduces analgesic requirements and reduces the 
anxiety of the patients. (  Eur J Anaesthesiol. 2002 Jan;19(1):52-6 ). 
5. Intrathecal versus intravenous fentanyl for supplementation of 
subarachnoid block during cesarean delivery  
 Sahar and Marie et al in 2002 conducted a randomized study in 48 
healthy parturient patients undergoing elective cesarean section. One 
group received 12 mg of  hyperbaric bupivacaine plus 12.5 µg of fentanyl 
intrathecally. Another group received 12 mg of hyperbaric bupivacaine 
intrathecally and 12.5 µg of fentanyl intravenously immediately after 
spinal. They found that additional intravenous fentanyl was needed in IV 
fentanyl group and incidence of hypotension and use of ephedrine was 
more in IV fentanyl group. The time to the first request for postoperative 
analgesia was significantly longer in the intrathecal fentanyl group than in 
the IV fentanyl group. They concluded that supplementation of spinal 
bupivacaine anesthesia for cesarean delivery with intrathecal fentanyl 
provides a better quality of anesthesia and is associated with a decreased 
incidence of side effects as compared with supplementation with the same 
dose of IV fentanyl (Anesth Analg 2002;95:209-213 ) 
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6. Intrathecal Magnesium Prolongs Fentanyl Analgesia 
 Asokumar Buvanendran  et  al  in  2002  were  one  of  the  first  to 
administer  magnesium  intrathecally  in  humans.  They  conducted  a  
prospective  randomized  controlled  trial  in  52  healthy  parturient  
mothers  requiring  labour  analgesia.  METHOD:  Patients  were 
randomized to receive either intrathecal fentanyl 25 µg plus saline  or 
fentanyl 25 µg plus magnesium sulfate 50 mg as part of a combined 
spinal-epidural technique. The duration of analgesia of the intrathecal 
drug combination was defined by the time of patient request for additional 
analgesia.  RESULT:  There was significant prolongation in the median 
duration of analgesia in the magnesium plus fentanyl group compared 
with the fentanyl alone group.  CONCLUSION:  They  concluded  that 
intrathecal magnesium prolongs spinal opioid analgesia in humans and 
suggest that the availability of an intrathecal N-methyl-D-aspartate 
antagonist could be of clinical importance for pain management. ( 
Anaesth Analg 2002;95:661-666 ). 
7. Effect of intraoperative magnesium infusion on perioperative 
analgesia in open cholecystectomy 
 Bhatia A et al in 2004 conducted a prospective, double-blinded, 
randomized study  in  50 ASA physical status I and II patients scheduled 
for elective open cholecystectomy with general anesthesia. METHOD:  
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patients were randomly allocated to receive MgSO4 or saline 
intravenously.  Patients in the magnesium group received 50% MgSO4 
(50 mg/kg) in 100 mL saline and those in the control group received an 
equal volume of saline i.v. during the preoperative period followed by 50 
ml/hr infusion of either MgSO4 (15 mg/kg/hr) or saline until the end of 
surgery. Morphine requirement, pain during rest and on coughing, 
discomfort, and insomnia were assessed during the postoperative period 
for 24 hours. CONCLUSION: They concluded the study by saying 
administration of intraoperative MgSO4 resulted in better pain relief and 
comfort in the first postoperative hour, but it did not significantly 
decrease the postoperative morphine requirement. Magnesium sulphate 
resulted in better sleep quality during the postoperative period, without 
any significant adverse effects. (  J Clin Anesth. 2004 Jun;16(4):262-5 ). 
8. The effect of adding intrathecal magnesium sulphate to 
morphine for postoperative analgesia after caesarean section 
 Khemakhem K  et  al in  2006  conducted  a  prospective, 
randomized, double blind, controlled study  to  know   the effect of 
intrathecal  magnesium sulphate, morphine and their  association in 
postoperative analgesia.  METHOD:  97  ASA I and II parturients 
undergoing cesarean section are  randomly allocated to 3  groups   to  
receive   0.1 mg  of morphine  or 100 mg  of  magnesium  or both. 
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Postoperative  analgesia  with the visual analogic score (VAS), analgesic 
requirement, and side effects were recorded.  CONCLUSION:  The 
addition of   intrathecal magnesium sulphate 100 mg to morphine   
improved quality and duration of the postoperative analgesia with a better 
maternal satisfaction without additional side effects. ( Euro J Anaes 2006 
jun; 23: 183-4). 
9. Role of magnesium as adjuvant to ropivacaine in caudal 
anaesthesia in children  
 H.Birbicer and D.Avlan et al in 2006 conducted a randomized trial 
in which 60 ASA I and II patients in age group of 2 – 10 years coming for 
lower abdominal and penoscrotal surgeries were included. METHOD : 
After general anaesthesia induction, caudal block given with 0.25% 
ropivacaine in volume of 0.5 ml/kg in one group and 0.25% ropivacaine 
with 50 mg magnesium as same volume in second group. Postoperative 
analgesia levels recorded at 15 min and 1, 2, 3, 4, 6 h by using Paediatric 
Objective Pain Scale (POPS) and The Children’s Hospital of Eastern 
Ontoria Pain Scale (CHEOPS). Postoperative motor blocks were 
evaluated with Modified Bromage Motor Block Scale. CONCLUSION : 
They concluded that addition of magnesium as an adjuvant agent to local 
anaesthetics for caudal analgesia has no effect on postoperative pain and 
analgesic need. ( Pediatric surgery international 2006;1779:195-198 ). 
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10. Epidural magnesium reduces postoperative analgesic       
requirements after hip surgery  
 A.Bilir and A.Ozcelik et al in 2007 conducted a randomized double 
blind study in 50 patients undergoing elective hip surgery. METHOD : 
Patients were enrolled to receive either fentanyl or fentanyl plus 
magnesium for 24 hours for epidural analgesia. All patients  were 
equipped with PCEA device and initial setting of a demand bolus dose of  
fentanyl 25 µg. Patients in magnesium group received magnesium 
sulphate epidurally as an initial bolus dose of 50 mg and continuous 
infusion of 100 mg/day. Ventilatory frequency, heart rate, blood pressure, 
pain assessment using visual analogue scale , sedation scores and fentanyl 
consumption  were recorded in postop period. CONCLUSION : They 
concluded that co-administration of magnesium for postoperative 
epidural analgesia results in a reduction of fentanyl consumption without 
any side effects. (BJA 2007 ;1093: 294-299 ). 
11. Combined intrathecal and epidural magnesium sulphate 
supplementation of spinal anaesthesia to reduce post-operative 
analgesia requirements 
 R.Arcioni  et al in 2007 conducted a prospective , randomized, 
double blind, controlled study in 120 ASA I and II patients coming for 
lower limb orthopedic surgery. METHOD : Patients were randomly 
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divide into 4 groups  assigned to receive intrathecal magnesium sulphate, 
epidural magnesium sulphate, combined  intrathecal and epidural 
magnesium sulphate or spinal anaesthesia alone. Post-operative morphine 
consumption  was assessed in all patients using PCA. CONCLUSION : In 
patients undergoing orthopedic surgery, supplementation of spinal 
anaesthesia with combined intrathecal and epidural magnesium 
significantly reduces the post-operative analgesic requirements. ( Acta 
Anaes Scand. 2007 ; 51(4): 482-489 ). 
12. Pre-incisional epidural magnesium provides pre-emptive and 
preventive analgesia in patients undergoing abdominal 
hysterectomy 
 S.Farouk et al in 2008 conducted a prospective randomized, 
double-blind study  designed to evaluate the pre-emptive and preventive 
analgesic efficacy of adding magnesium to a multimodal regimen of 
patient-controlled epidural analgesia (PCEA) in patients undergoing 
abdominal hysterectomy. CONCLUSION: Continuous epidural 
magnesium started before anaesthesia provided pre-emptive, preventive 
analgesia, and an analgesic-sparing effect that improved postoperative 
analgesia without increasing the incidence of side-effects. ( BJA 2008 
101(5): 694-699 ). 
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13. Analgesic requirements for patients undergoing lower 
extremity orthopedic surgery -  the effect of combined spinal 
and epidural magnesium 
 H.El-Kerdawy et al in 2008 conducted a randomized control study 
on 80 ASA I and ASA II patients coming for elective orthopedic lower 
limb surgery. METHOD : Patients were randomly allocated into two 
groups , control group received intrathecal 10 mg of 0.5% bupivacaine( 2 
ml ) plus 25 µg of Fentanyl (0.5 ml), plus 0.9% NaCl solution (1 ml) and 
an epidural infusion of 0.9% NaCl at a rate of 5 ml/hr. The Magnesium 
Group: patients received intrathecal 10 mg of Bupivacaine 0.5% (2 ml), 
plus 25 µg of Fentanyl (0.5 ml), plus 50 mg of 5% Mg (1 ml) and an 
epidural infusion of 2% Mg at a rate of 100 mg/hr (5 ml/hr). RESULTS: 
Intrathecal Mg prolonged fentanyl analgesia as indicated by increased 
duration of anesthesia in the Mg group, and thus improving the quality of 
spinal anesthesia. The effectiveness of the postoperative analgesia was 
confirmed by markedly lower perioperative analgesic requirements (38.3 
% less than the Control group), the patient's low VAS score, the longer 
time for the patients first requirement  of  post-operative analgesia in the 
Mg group. CONCLUSION: They concluded, for lower extremity 
orthopedic procedure, supplementation of spinal anesthesia with 
combined intrathecally injected and epidurally infused Mg, considerably 
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reduced the perioperative analgesic requirements without any side effects. 
( Middle East J Anaes 2008 Jun;19(5):1013-25). 
14. Comparison of intrathecal magnesium, fentanyl, or placebo combined 
with bupivacaine 0.5% for parturients undergoing elective 
cesarean delivery 
 Unlugenc and Ozalevli et al in  march 2009 conducted a 
prospective, randomized, double-blind study to investigate the sensory, 
motor, and analgesic block characteristics of intrathecal magnesium 50 
mg compared with fentanyl 25 µg and saline when added to 0.5% 
bupivacaine. METHOD : 90 ASA I and II healthy parturients undergoing 
elective cesarean section were included in the study. Onset and duration 
of sensory and motor block,  maximal sensory block height, the time to 
reach the maximal dermatomal level of sensory block, and the duration of 
spinal anesthesia were rocorded. CONCLUSION : They concluded that in 
patients undergoing cesarean section with spinal anesthesia, the addition 
of magnesium sulfate (50Ԝmg) intrathecally  to 10Ԝmg of spinal 
bupivacaine (0.5%) did not shorten the onset time of sensory and motor 
blockade or prolong the duration of spinal anesthesia, as seen with 
fentanyl. ( Acta Anaes Scand 2009: 53 : 346-353). 
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MATERIALS AND METHODS 
Patient selection: 
 The study population consist of 40 ASA I & ASA II patients in the 
age group of 18 years to 65 years admitted to undergo elective 
orthopaedic lower limb surgeries at Govt. Stanley Hospital, Chennai 
during the period of May  2009 to August 2009. After getting approval 
from the institutional ethical committee and after obtaining written 
informed  consent from each patient ,the study was conducted. 
Inclusion criteria: 
1.  Age Group 18 – 65 years 
2. ASA I and ASA II 
3. Elective orthopaedic lower limb surgeries 
4. Duration of Surgery between 1:00 to 2:30 hours. 
Exclusion criteria:  
     1.  Patient refusal       
     2.  Patients with preexisting  renal problems 
     3.  Allergy to any of the study medications  
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    4.  Preoperative hypotension 
    5.  Local infection at lumbar area 
    6.  Pre-existing neurological disorders 
    7.  Coagulation defects and patient on anticoagulants  
Preoperative assessment: 
- Routine clinical examination 
- Biochemical investigations 
- Electrocardiogram and chest x-ray were examined 
thoroughly for the conduct of anaesthesia. 
Conduct of anaesthesia 
Patients were allocated randomly  into two equal   groups (20 in 
each group). Group P (placebo)  received intrathecal 10 mg of hyperbaric 
bupivacaine 0.5% ( 2ml ) plus 25 µg of fentanyl ( 0.5 ml ) plus 0.9% 
NaCl solution ( 1 ml ) . Total intrathecally injected volume is 3.5 ml. 
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Epidural infusion of 0.9% NaCl solution is given in first hour of surgery 
at the rate of 5 ml/hr. 
Group M ( Magnesium) received intrathecal 10 mg of hyperbaric 
bupivacaine 0.5% ( 2 ml ) plus 25 µg of fentanyl ( 0.5 ml ) plus 50 mg of 
5% magnesium sulphate ( 1 ml ). Total intrathecally injected volume is 
3.5 ml. Epidural infusion of  2 % magnesium sulphate is given at the rate 
of 100 mg/hr ( 5 ml/hr ) during first hour of surgery. 
  5 % magnesium sulphate solution is prepared by mixing 1 ml of  
50%  magnesium sulphate with 9 ml of preservative free sterile water. 2% 
magnesium sulphate is prepared by mixing 1 ml of 50% magnesium 
sulphate with 24 ml of preservative free sterile water. 
 No premedication was given. On arrival in the operating room, 
baseline cardiorespiratory parameters viz., Heart Rate(HR), Systolic 
blood pressure(SBP), Diastolic blood pressure(DBP),Mean arterial 
pressure(MAP), Respiratory rate(RR) and Ramsay Sedation Score(RSS) 
were recorded. 
A good intravenous access was established using 18G IV cannula. 
Preloading was done with crystalloids (10 ml/kg). 
A standard anaesthetic technique was followed in all patients. 
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With the patient in sitting posture, after informing the procedure to 
the patient & under strict aseptic precautions, epidural space was 
identified at L2-L3 interspace using 16G Tuohy needle by loss of 
resistance technique. 18G epidural catheter was threaded in a cephalad 
direction & 3 cm catheter length was kept inside the epidural space. A 
test dose of 3 cc of 1.5 % lignocaine with adrenaline (5 µg/ml) was given. 
Spinal anaesthesia is performed at L3-L4 interspace. Epidural catheter 
was fixed and secured with tapes.The epidural catheter is then connected 
to infusion pump that is disconnected after first hour of surgery. 
Patients with duration of surgery between 1-2:30 hours were only 
included in the study. Unanticipated prolonged duration of surgery  were 
excluded from the study. 
Time of incision is noted. 
Intra-operatively the patient was monitored with ECG, BP and 
SpO2. 
The following parameters were  monitored every 10 mins: 
1. Heart rate (HR) 
2. Systolic blood pressure (SBP) 
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3. Diastolic blood pressure (DBP) 
4. Mean arterial pressure (MAP) 
 5.  Respiratory rate (RR) 
6. Oxygen saturation (SpO2) 
Ramsay sedation scale (RSS) was also noted every 30 min during  
intraoperative  period. 
Urine output was monitored hourly. 
All patients were given oxygen supplementation (4-5 L/min) 
through Hudson’s face mask. No intravenous opioid analgesics were 
supplemented during the study. Intravenous fluid management was done 
based on mean arterial blood pressure and surgical blood loss. 
RAMSAY SEDATION SCALE: 
1. Patient is anxious and agitated or restless, or both 
2. Patient is co-operative, oriented and tranquil 
3. Patient responds to commands only 
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4.  Patient exhibits brisk response to glabellar tap or loud 
auditory stimulus 
5. Patient exhibits sluggish response to glabellar tap or loud 
auditory  stimulus.                                                                                                                
6. Patient exhibits no response 
POST- OPERATIVE MONITORING : 
- The epidural catheter was retained in position. 
Postoperatively the patient was transferred to the Post 
Anaesthetic Care Unit( PACU) where PR,SBP ,DBP, SPO2 
& RR  monitored continuously and recorded every hour.  
- The intensity of pain was measured by using the verbal 
rating pain scale. 
Pain Score (Verbal Rating Score): 
Grade 0 - No complaint of pain 
Grade 1 - Patient complaints of pain but tolerable (mild pain) 
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Grade 2  - Patient complaining of severe pain and demands relief  
   (Moderate pain)                                                                                     
Grade 3 - Patient restless and screaming with pain(Severe pain) 
When the patient complaints of pain , the pain intensity was 
assessed based on verbal rating scale & if pain score reaches 1, epidural 
top up of  6ml of 0.125% bupivacaine was given to the patient. 
The time of first rescue analgesia(TFA) was calculated from the 
time of injection of study drug in the central neuraxial block to the time 
when the verbal rating pain score reached 1 in the postop period.  
Number of epidural top-ups (6 ml of 0.125% bupivacaine) required 
by each patient for a period of 48 hours was noted in both the groups. 
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OBSERVATIONS 
LIST OF ORTHOPAEDIC LOWER LIMB SURGERIES 
S.NO DIAGNOSIS AND SURGICAL   
PROCEDURES 
NO. OF CASES 
GROUP P GROUP M
1. Fracture shaft of femur- ORIF 
with interlocking nailing / plating 
6 7 
2. Fracture both bones leg- ORIF 
with intramedullary nailing / 
plating 
6 5 
3. Fracture neck of femur- 
Hemiarthroplasty 
5 5 
4. Supracondylar fracture femur – 
ORIF with Dynamic Condylar 
Screw (DCS) 
2 3 
5. Fracture Patella- ORIF with 
Tension Band Wiring 
1 - 
 TOTAL CASES 20 20 
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STATISTICS AND ANALYSIS  
40 Patients were allocated randomly  into two equal   groups (20 in 
each group). Group P (placebo)  received intrathecal 10 mg of hyperbaric 
bupivacaine 0.5% ( 2 ml ) plus 25 µg of fentanyl ( 0.5 ml ) plus 0.9% 
NaCl solution ( 1 ml ) . Total intrathecally injected volume is 3.5 ml. 
Epidural infusion of 0.9% NaCl solution is given in first hour of surgery 
at the rate of 5 ml/hr. 
Group M ( Magnesium) received intrathecal 10 mg of hyperbaric 
bupivacaine 0.5% ( 2 ml ) plus 25 µg of fentanyl ( 0.5 ml ) plus 50 mg of 
5% magnesium sulphate ( 1 ml ). Total intrathecally injected volume is 
3.5 ml. Epidural infusion of  2 % magnesium sulphate is given at the rate 
of 100 mg/hr ( 5 ml/hr ) during first hour of surgery. 
A standard anaesthetic technique was followed in all patients. The 
patient were assessed by the same observer in the postoperative period. 
All the data were expressed as mean ± standard deviation (SD). 
Qualitative variables were compared with `Chi-square test’ and 
quantitative variables were compared with ‘the student ‘t’ test’. The level 
of statistical significance was set at P < 0.05. 
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DEMOGRAPHIC PROFILE 
 
TABLE- 1 
COMPARISON OF AGE DISTRIBUTION 
 
S.NO PARAMETERS GROUP P VALUE 
GROUP P GROUP 
M 
MEAN ± 
SD 
MEAN ± 
SD 
1. Age (yrs) 40.60 ± 
7.40 
36.85 ± 
9.59 
P-0.183(NOT 
SIGNIFICANT) 
 
 
 
Figure 1: BOX- PLOT compares the age distribution of GROUP P 
and GROUP M 
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TABLE – 2 
 
SEX DISTRIBUTION 
   
 GROUP P GROUP M TOTAL 
MALE 15 (75%) 17 (85%) 32 (80%) 
FEMALE 5 (25%) 3 (15%) 8 (20%) 
TOTAL 20 20 40 
 
 
TABLE – 3 
COMPARISON OF HEIGHT AND WEIGHT 
S.NO PARAMETERS
GROUP 
P value GROUP P GROUP M 
MEAN±SD MEAN±SD 
1. HEIGHT 164.00±5.73 166.65±6.01 P-0.152(Not 
Significant) 
2. WEIGHT 59.60±5.16 59.50±6.10 P-0.956(Not 
Significant) 
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FIGURE – 2 
 
SEX DISTRIBUTION 
 
 
 
 
FIGURE – 3 
 
HEIGHT AND WEIGHT 
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TABLE - 5  
 
HEART RATE 
 
S NO. PARAMETERS(MINUTES) 
GROUP 
P VALUE 
P<0.05-SIG 
 
GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
1. HR PRE-OP 94.10 ± 11.81 97.05 ± 12.81 .441(NOT SIG) 
2. HR10 92.20 ± 8.16 94.70 ± 11.69 .438(NOT SIG) 
3. HR20 88.90 ± 8.70 90.40 ± 12.12 .656(NOT SIG) 
4. HR30 85.95 ± 7.52 87.30 ± 11.77 .668(NOT SIG) 
5. HR40 84.80 ± 8.29 87.10 ± 12.81 .504(NOT SIG) 
6. HR50 83.85 ± 8.34 85.45 ± 13.03 .646(NOT SIG) 
7. HR60 82.75 ± 8.66 84.90 ± 11.79 .515(NOT SIG) 
8. HR70 81.95 ± 9.24 82.55 ± 10.73 .851(NOT SIG) 
9. HR80 82.35 ± 8.96 81.65 ± 9.9.52 .812(NOT SIG) 
10. HR90 83.00 ± 9.59 82.00 ± 11.94 .908(NOT SIG) 
11. HR100 84.55 ± 9.02 83.6 ± 10.51 .761(NOT SIG) 
12. HR110 86.30 ± 7.55 85.7 ± 10.26 .834(NOT SIG) 
13. HR120 84.15 ± 10.00 86.85 ± 10.21 .594(NOT SIG) 
14. HR130 87.30 ± 8.41 86.20 ± 10.28 .713(NOT SIG) 
15. HR140 87.00 ± 8.60 88.65 ± 11.08 .602(NOT SIG) 
16. HR150 90.70 ± 8.98 90.70 ± 10.53 1.00(NOT SIG) 
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TABLE - 6 
 
SYSTOLIC BLOOD PRESSURE 
 
S NO. PARAMETERS (MINUTES) 
GROUP 
P VALUE 
P<0.05- SIG 
GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
1. SBP PRE-OP 128.80 ± 6.68 130.20 ± 6.47 0.505(NOT SIG) 
2. SBP 10 120.20 ± 11.70 118.65 ± 5.85 0.600(NOT SIG) 
3. SBP 20 110.05  ± 11.64 107.40 ± 10.88 0.462(NOT SIG) 
4. SBP 30 113.85 ± 13.51 112.70 ± 6.85 0.736(NOT SIG) 
5. SBP 40 114.90 ± 9.29 108.30 ± 22.37 0.231(NOT SIG) 
6. SBP 50 116.00 ± 8.57 111.05 ± 7.16 0.055(NOT SIG) 
7. SBP 60 115.70 ± 9.81 110.25 ± 5.98 0.041(SIG) 
8. SBP 70 116.00 ± 7.38 108.70 ± 8.97 0.008(SIG) 
9. SBP 80 114.80 ± 7.96 112.95 ± 7.51 0.454(NOT SIG) 
10. SBP 90 114.50 ± 7.04 111.80 ± 8.47 0.280(NOT SIG) 
11. SBP 100 113.65 ± 8.56 110.35 ± 7.88 0.212(NOT SIG) 
12. SBP 110 118.35 ± 5.38 112.45 ± 7.30 0.006(SIG) 
13. SBP 120 120.35 ± 5.33 113.75 ± 8.90 0.007(SIG) 
14. SBP 130 117.55 ± 5.05 113.00 ± 8.37 0.044(SIG) 
15. SBP 140 118.70 ± 6.34 114.80 ± 7.46 0.083(NOT SIG) 
16. SBP 150 
 
124.10 ± 3.74 
 
120.00 ± 8.03 0.045(SIG) 
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FIGURE – 5 
 
HEART RATE 
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TABLE – 7 
 
DIASTOLIC BLOOD PRESSURE 
 
S NO. PARAMETERS (MINUTES) 
GROUP 
P VALUE 
P<0.05- SIG 
GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
1. DBP PRE OP 82.40 ± 3.01 81.85 ± 4.93 0.673(NOT SIG) 
2. DBP 10 75.20 ± 8.70 74.00± 6.02 0.615(NOT SIG) 
3. DBP 20 68.15± 10.38 65.50 ± 10.18 0.420(NOT SIG) 
4. DBP 30 69.40 ± 9.63 69.15 ± 6.36 0.923(NOT SIG) 
5. DBP 40 71.60 ± 7.80 67.65 ± 15.14 0.306(NOT SIG) 
6. DBP 50 72.20 ± 8.35 68.70 ± 4.47 0.107(NOT SIG) 
7. DBP 60 73.20 ± 7.88 67.85 ± 3.74 0.009(SIG) 
8. DBP 70 72.55 ± 7.75 66.95 ± 5.60 0.013(SIG) 
9. DBP 80 71.75 ± 6.48 70.70± 4.95 0.568(NOT SIG) 
10 DBP 90 72.65 ± 6.55 69.45 ± 4.87 0.088(NOT SIG) 
11. DBP 100 72.50 ± 7.49 69.85 ± 5.54 0.211(NOT SIG) 
12. DBP 110 74.30 ± 5.10 70.45 ± 4.42 0.015(SIG) 
13. DBP 120 75.35 ± 6.67 71.85 ± 5.61 0.080(NOT SIG) 
14. DBP 130 73.30 ± 5.19 70.95 ± 5.07 0.156(NOT SIG) 
15. DBP 140 74.90 ± 6.20 71.65 ± 4.33 0.062(NOT SIG) 
16. DBP 150 79.15 ± 3.04 78.10 ± 4.61 0.401(NOT SIG) 
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TABLE – 8 
 
MEAN ARTERIAL PRESSURE 
 
S 
NO. 
PARAMETERS 
(MINUTES) 
GROUP 
P VALUE 
P<0.05- SIG 
GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
1. MAP PRE OP 97.85 ± 3.51 97.90 ± 4.74 0.970(NOT SIG) 
2. MAP 10 90.40 ± 9.34 88.80 ± 5.61 0.516(NOT SIG) 
3. MAP 20 81.85 ± 10.05 78.85 ± 10.35 0.359(NOT SIG) 
4. MAP 30 83.85 ± 9.94 83.80 ± 5.52 0.984(NOT SIG) 
5. MAP 40 86.20 ± 8.15 84.65 ± 4.58 0.463(NOT SIG) 
6. MAP 50 86.70 ± 8.15 83.00 ± 4.66 0.086(NOT SIG) 
7. MAP 60 88.25 ± 8.97 82.05 ± 4.31 0.008(SIG) 
8. MAP 70 86.90 ± 7.38 80.85 ± 6.44 0.009(SIG) 
9. MAP 80 86.00 ± 6.58 84.70 ± 5.55 0.504(NOT SIG) 
10. MAP 90 86.40 ± 6.32 83.45± 5.77 0.132(NOT SIG) 
11. MAP 100 85.85 ± 7.76 83.65± 5.31 0.302(NOT SIG) 
12. MAP 110 89.35 ± 5.30 84.60 ± 5.04 0.006(SIG) 
13. MAP 120 89.80 ± 6.13 85.85 ± 6.22 0.050(NOT SIG) 
14. MAP 130 88.25 ± 4.35 85.05 ± 5.79 0.055(NOT SIG) 
15. MAP 140 88.90 ± 6.07 86.20 ± 4.80 0.127(NOT SIG) 
16. MAP 150 94.00 ± 2.95 91.75 ± 5.15 0.098(NOT SIG) 
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FIGURE – 7 
 
DIASTOLIC BLOOD PRESSURE 
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TABLE – 9 
 
RESPIRATORY RATE 
 
S 
NO. 
PARAMETERS 
(MINUTES) 
GROUP 
P VALUE 
P<0.05- SIG 
GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
1. RR PRE OP 15.80 ± 1.58 19.75 ± 1.56 0.268(NOT SIG) 
2. RR 10 14.45 ± 1.47 15.20 ± 1.28 0.093(NOT SIG) 
3. RR 20 14.65 ± 1.87 15.10 ± 1.41 0.396(NOT SIG) 
4. RR 30 14.40 ± 2.37 14.55 ± 1.76 0.822(NOT SIG) 
5. RR 40 14.10 ± 2.04 14.30 ± 1.45 0.724(NOT SIG) 
6. RR 50 14.25 ± 1.58 14.30 ± 1.49 0.919(NOT SIG) 
7. RR 60 14.45 ± 2.01 14.45±1.27 1.000(NOT SIG) 
8. RR 70 14.55 ± 2.44 14.65 ± 1.27 0.872(NOT SIG) 
9. RR 80 14.70 ± 2.12 14.85 ± 1.35 0.792(NOT SIG) 
10 RR 90 14.50 ± 1.76 14.35 ± 1.56 0.777(NOT SIG) 
11. RR 100 14.60 ± 1.50 14.35 ± 1.35 0.583(NOT SIG) 
12. RR 110 14.80 ± 1.73 14.40 ± 1.53 0.445(NOT SIG) 
13. RR 120 14.75 ± 2.07 14.80 ± 1.05 0.923(NOT SIG) 
14. RR 130 15.50 ± 2.91 15.00 ± 1.17 0.480(NOT SIG) 
15. RR 140 14.95± 1.47 14.90 ± 0.97 0.899(NOT SIG) 
16. RR 150 15.00 ± 1.45 15.05 ± 0.99 0.900(NOT SIG) 
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TABLE – 10 
 
RAMSAY SEDATION SCALE 
  
RSS GROUP P GROUP M TOTAL 
30 
1 COUNT 
%WITH IN GROUP 
20 
100% 
12 
60% 
32 
80% 
2  COUNT 
                  %WITH IN   GROUP 
0 
0% 
8 
40% 
8 
20% 
60 
1       COUNT 
%WITH IN GROUP 
20 
100% 
0 
0% 
20 
50% 
2       COUNT 
                     %WITH IN GROUP 
0 
0% 
20 
100% 
20 
50% 
90 
1       COUNT 
%WITH IN GROUP 
20 
100% 
6 
30% 
26 
65% 
2       COUNT 
                     %WITH IN GROUP 
0 
0% 
14 
70% 
14 
35% 
120 
1        COUNT 
%WITH IN GROUP 
20 
100% 
19 
95% 
39 
97.5% 
2       COUNT 
                     %WITH IN GROUP 
0 
0% 
1 
5% 
1 
2.5 
150 
1           COUNT 
%WITH IN GROUP 
20 
100% 
20 
100% 
40 
100% 
 
 According to Chi- square test, RSS was significant at 30 min (P-
0.003), 60 min (P<0.001) and 90 min (P<0.001). RSS was not significant 
at 120 min and 150 min respectively. 
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FIGURE – 9 
 
RESPIRATORY RATE 
 
 
 
 
FIGURE – 10 
 
RAMSAY SEDATION SCALE 
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TABLE – 11 
 
VERBAL RATING SCALE 
 
TIME 
IN 
HOURS 
VERBAL RATING SCALE GROUP P 
GROUP 
M 
TOTAL 
CHI-
SQUARE 
TEST 
2 
0        COUNT 
  %WITH IN GROUP 
18 
90% 
20 
100% 
38 
95% 
P-0.487 
NOT SIG 
 2            COUNT 
                    %WITH IN GROUP 
2 
10% 
0 
0% 
2 
5% 
4 
0        COUNT 
                    %WITH IN GROUP 
0 
0% 
19 
95% 
19 
47.5% 
P<0.001 
SIG 
1            COUNT 
                     %WITH IN GROUP 
16 
80% 
1 
5% 
17 
42% 
2            COUNT 
                     %WITH IN GROUP 
4 
20% 
0 
0% 
4 
10% 
6 
0         COUNT 
                     %WITH IN GROUP 
6 
30% 
8 
40% 
14 
35% 
P-0.741 
NOT SIG 
1         COUNT 
                     %WITH IN GROUP 
14 
70% 
12 
60% 
26 
65% 
8 
0         COUNT 
  %WITH IN GROUP 
0 
0% 
4 
20% 
4 
10% 
P-0.072 
NOT SIG 
1         COUNT 
                     %WITH IN GROUP 
19 
95% 
16 
80% 
35 
87.5% 
2         COUNT 
                     %WITH IN GROUP 
1 
5% 
0 
0% 
1 
2.5% 
12 
0         COUNT 
  %WITH IN GROUP 
0 
0% 
2 
10% 
2 
5% 
P<0.001 
SIG 
1         COUNT 
                     %WITH IN GROUP 
7 
35% 
18 
90% 
25 
62.5% 
2         COUNT 
                     %WITH IN GROUP 
13 
65% 
0 
0% 
13 
32.5% 
18 
1             COUNT 
   %WITH IN GROUP 
5 
25% 
15 
75% 
20 
50% 
P-0.004 
SIG 
2         COUNT 
                     %WITH IN GROUP 
15 
75% 
5 
25% 
20 
50% 
24 
1             COUNT 
   %WITH IN GROUP 
1 
5% 
11 
55% 
12 
30% 
P-0.001 
SIG 
2             COUNT 
                     %WITH IN GROUP 
19 
95% 
9 
45% 
28 
70% 
36 
1         COUNT 
  %WITH IN GROUP 
18 
90% 
20 
100% 
38 
95% 
P-0.487 
NOT SIG 
2         COUNT 
                     %WITH IN GROUP 
2 
10% 
0 
0% 
2 
5% 
48 
0         COUNT 
  %WITH IN GROUP 
0 
0% 
2 
10% 
2 
5% 
P-0.487 
NOT SIG 
1         COUNT 
                     %WITH IN GROUP 
20 
100% 
18 
90% 
38 
95% 
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FIGURE  - 11 
 
VERBAL RATING SCALE 
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TABLE – 12 
 
TIME OF FIRST RESCUE ANALGESIA 
 
 
GROUP 
P VALUE GROUP P GROUP M 
MEAN ± SD MEAN ± SD 
Time of first 
rescue 
analgesia(hrs) 
3.27 ±0.53 6.05 ± 0.65 
0.001 
SIGNIFICANT 
 
  
0
5
10
15
20
25
  
57
FIGURE – 12 
 
 
 
 
TABLE – 13 
 
NO.OF POST OPERATIVE EPIDURAL TOP-UPS 
        
GROUPS NO. OF EPIDURAL TOP 
UPS 
AVERAGE NO. 
OF EPIDURAL 
TOP UP 4 5 6 7 
GROUP    P 
GROUP   M 
- 
19 
- 
1 
15 
- 
5 
- 
6.25 
4.05 
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DISCUSSION 
 
Our knowledge of acute pain mechanisms has advanced 
sufficiently over the past decade so that rational rather than empirically 
derived therapy can be used by aiming specifically at interrupting the 
mechanisms responsible for the generation of clinical pain. Breakthrough 
pain after surgical procedures is now beginning to be recognized as 
constituting suboptimal management. This is an active research area. A 
number of clinical trials have been conducted to prove the efficacy of 
anti- nociceptive effect of magnesium  using different techniques and 
different types of drugs with conflicting results. The use of epidural 
techniques also offer the advantage of effective prolonged postoperative 
analgesia as compared to nerve blocks and local infiltrations. 
 
Noxious stimulation leads to the release of neurotransmitters which 
bind to various subclasses of excitatory amino acid receptors, including 
NMDA receptors. So NMDA receptor antagonists may play a role in the 
prevention and treatment of post injury pain. Magnesium blocks calcium 
influx and non-competitively antagonizes NMDA receptor channels25.  
Non competitive NMDA receptor antagonists can have an effect on pain 
when used alone, but it has also been shown that they can reveal the 
analgesic properties of opioids2, 25 . 
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 The safety of intrathecal and epidural magnesium  administration 
has been evaluated in animal and human studies that concluded that 
magnesium has a good safety profile  with no serious side effects26, 27 . 
Since the amount of magnesium used in this is study   is only 150 mg ( 50 
mg intrathecally and 100 mg through epidural infusion), serum 
magnesium levels was not monitored during the study. In this study we 
found that  magnesium administered intrathecally and epidurally  reduced 
the amount of analgesic that patients required postoperatively suggesting 
that magnesium  may enhance the analgesic effect of bupivacaine and 
fentanyl. 
          In this  randomized control study, we have evaluated the analgesic 
efficacy of bupivacaine with fentanyl and magnesium  mixture given 
through spinal route and epidural magnesium in patient undergoing 
elective orthopaedic lower limb surgeries. 
          The level of sedation intraoperatively was monitored using Ramsay 
Sedation Scale. The patients in group M were well sedated and 
comfortable than in group P. 
         Pain intensity was assessed using the verbal rating scale (VRS) 
post-operatively. Significant lower VRS scores after 
2,4,6,8,12,18,24,26,48 hours has in group M demonstrated the clinical 
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advantage of administering mixture of bupivacaine, fentanyl and 
magnesium through spinal route for effective postoperative analgesia. 
 Duration of analgesia was significantly more in group M patients 
receiving bupivacaine, fentanyl and magnesium mixture (  6.05±0.64 hrs) 
as compared to group P (  3.26±0.53 hrs ). The demand for supplementary 
epidural top-ups over 48 hours postoperatively was significantly low  in  
group M than group P. 
 Hala El-Kerdawy et al22  in 2008 conducted a similar study but 
they had a little different results. Duration of spinal anaesthesia was 
prolonged in magnesium group ( 182.8±19.1 mins ) when compared to 
placebo group ( 164.4±16.9 mins ). In our study the duration of spinal 
anaesthesia in magnesium group is 363±38 mins when compared to 
placebo group( 195±32 mins ). The difference in the results may be 
explained by the fact that El-Kerdawy et al performed spinal at L3-L4 
interspace or L4-L5 interspace whereas we did it in L2-L3 space and L3-
L4 interspace. Total intrathecally injected volume of drug is also 
different. They used 3 ml whereas in our study it is 3.5 ml. 
 Time for first rescue analgesia is also different in both studies. In 
our study, time for first rescue analgesia (TFA)  in magnesium group is 
363±38 mins. But in my parent study, time for first rescue analgesia 
(TFA ) in magnesium group is 79 mins. This gross difference can be 
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explained by difference in the definition of TFA in both studies. El-
Kerdawy et al defined time for first rescue analgesia as the time from the 
completion of surgery till the time of first use of rescue medication by 
PCEA. Since each surgery may have different durations, in our study, we 
defined time for first rescue analgesia as the time from the injection of the 
study drug in spinal anaesthesia  to the time when verbal rating pain score 
reaches 1 in the postoperative period. 
 Two patients of placebo group (10% of group P) and two 
patients of magnesium  group (10% of group M) had episodes of 
hypotension with a MAP< 70 mm Hg during intraoperative period who 
were managed with a single dose of ephedrine 6 mg iv and crystalloids , 
and this may be as a result of epidural bupivacaine as such. 
 Postoperatively none of the patients had episode of hypotension. 
No incidence of any bradycardia was noted in both the group during 
intraoperative and postoperative period. 
 The significant decrease in postoperative analgesic use obtained 
in this study is comparable with other studies5, 19, 20  that proved that 
intrathecal and epidural magnesium prolongs opioid analgesia and reduce 
postoperative analgesic requirements. 
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 This finding is different from some studies16, 18  which suggests 
that magnesium is not effective in anaesthesia. Their finding can be 
explained by the different route of  magnesium administration ( 
intravenous ) they used,which may lead us to the fact that the true site of 
action of magnesium is spinal cord NMDA receptors17. 
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SUMMARY 
This randomized control study was designed  to assess the 
effectiveness of using intrathecal and epidural magnesium (Mg )  in 
reducing intra and post operative analgesic requirements and to compare 
the quality of analgesia of intrathecal bupivacaine-fentanyl-magnesium 
mixture with intrathecal bupivacaine-fentanyl mixture. 
Forty ASA I & II patients undergoing elective orthopaedic lower 
limb surgical procedure under epidural anaesthesia were randomly 
allocated into one of the two groups.. Group P (placebo)  received 
intrathecal 10 mg of hyperbaric bupivacaine 0.5% ( 2 ml ) plus 25 µg of 
fentanyl ( 0.5 ml ) plus 0.9% NaCl solution ( 1 ml ) . Total intrathecally 
injected volume is 3.5 ml. Epidural infusion of 0.9% NaCl solution is 
given in first hour of surgery at the rate of 5 ml/hr. 
Group M ( Magnesium) received intrathecal 10 mg of hyperbaric 
bupivacaine 0.5% ( 2 ml ) plus 25 µg of fentanyl ( 0.5 ml ) plus 50 mg of 
5% magnesium sulphate ( 1 ml ). Total intrathecally injected volume is 
3.5 ml. Epidural infusion of  2 % magnesium sulphate is given at the rate 
of 100 mg/hr ( 5 ml/hr ) during first hour of surgery. 
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Pain in the post-operative period was assessed using a verbal rating 
scale (VRS). Time of first rescue analgesic(TFA) and the supplementary 
analgesic doses required for 24 hours were noted for the two groups. Pain 
score were significantly less in Group M at 2,4,6,8,12,24,48 hours (P 
<0.05) than in group P. Overall pain score over 48 hours period also 
revealed better pain relief in group M (P<0.05) as compared to Group P. 
Time of first rescue analgesic (TFA) in group M was significantly 
prolonged compared with group P. The postoperative analgesic 
consumption was also significantly less in group M than in group P. The 
incidence of hypotension did not differ significantly between the two 
groups & there was no bradycardia in both the groups. 
So this study demonstrates that addition of  magnesium to 
bupivacaine-fentanyl mixture definitely improves the quality of analgesia 
by reducing the overall pain score, prolonging the duration of the time of 
first rescue analgesia and causing reduction of total analgesic 
consumption in the postoperative period without any hemodynamic 
instability. 
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CONCLUSION 
1. Single dose administration of  intrathecal and epidural magnesium          
to intrathecal bupivacaine-fentanyl mixture provides effective 
postoperative analgesia in patients undergoing elective orthopaedic 
lower limb surgeries,   without any hemodynamic instability.        
2. Epidural magnesium significantly reduces the postoperative           
analgesic requirements. 
